Huber H, Edenhofer S, von Tresckow J, Robrecht S, et al. Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia. Blood 2021 Dec 15. pii: 483086. doi: 10.1182/blood.2021013208.
PMID: 35108374